Aligos Therapeutics, Inc.
ALGS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $1 | $12 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $1 | $12 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -74.6% | 11.7% | 219% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,193.5% | -547.7% | -675.2% | -2,857.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3,326% | -564.6% | -690.6% | -2,944.1% |
| EPS Diluted | -20.94 | -3.52 | -2.25 | -3.22 |
| % Growth | -494.9% | -56.4% | 30.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |